Novartis Announces CFO Transition with Mukul Mehta’s Appointment

Novartis ( (NVS) ) just unveiled an update.

On July 17, 2025, Novartis announced the appointment of Mukul Mehta as the new Chief Financial Officer, effective March 16, 2026, succeeding Harry Kirsch who will retire after a 22-year career with the company. This leadership transition is expected to continue the company’s strategic focus on growth and transformation, as Mukul brings extensive experience and expertise in finance and the pharmaceutical industry, positioning Novartis for its next phase of growth.

The most recent analyst rating on (NVS) stock is a Hold with a $125.00 price target. To see the full list of analyst forecasts on Novartis stock, see the NVS Stock Forecast page.

Spark’s Take on NVS Stock

According to Spark, TipRanks’ AI Analyst, NVS is a Outperform.

Novartis receives a strong overall score due to its solid financial performance and positive earnings call. The company’s profitability metrics and cash flow management are impressive, supporting sustainable growth. The bullish technical trend is tempered by potential overbought signals. Valuation is fair, providing a reasonable entry point for investors. Positive earnings call guidance and sentiment further bolster the stock’s attractiveness, despite some operational challenges.

To see Spark’s full report on NVS stock, click here.

More about Novartis

Novartis is an innovative medicines company focused on reimagining medicine to improve and extend people’s lives. Their products reach nearly 300 million people worldwide, empowering patients, healthcare professionals, and societies in the face of serious diseases.

Average Trading Volume: 1,575,411

Technical Sentiment Signal: Buy

Current Market Cap: $228.1B

For detailed information about NVS stock, go to TipRanks’ Stock Analysis page.